RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance.
Animals
Bacterial Load
/ drug effects
Biomarkers
Disease Models, Animal
Echocardiography
Eicosapentaenoic Acid
/ analogs & derivatives
Flow Cytometry
Gene Expression Regulation
/ drug effects
Heart Diseases
/ diagnosis
Heart Function Tests
Immunity
/ drug effects
Inflammation Mediators
/ metabolism
Lipid Metabolism
/ drug effects
Macrophages
/ immunology
Mice
Models, Biological
Phagocytosis
/ drug effects
Prognosis
Sepsis
/ complications
Signal Transduction
/ drug effects
bacterial clearance
cardiomyopathy
immune response
polymicrobial sepsis
resolvin E1
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
06
2020
accepted:
30
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
23
4
2021
Statut:
epublish
Résumé
The development of cardiac dysfunction caused by microbial infection predicts high mortality in sepsis patients. Specialized pro-resolving mediators (SPMs) mediate resolution of inflammation in many inflammatory diseases, and are differentially expressed in plasma of sepsis patients. Here, we investigated whether the levels of SPMs are altered in the murine septic heart following polymicrobial sepsis-induced cardiac dysfunction. Ten weeks-old male C57BL/6 mice were subjected to polymicrobial sepsis induced by cecal ligation and puncture (CLP), which is a clinically relevant sepsis model receiving analgesics, antibiotics, and fluid resuscitation. CLP caused a significant systolic dysfunction assessed by echocardiography. The hearts were subjected to LC-MS/MS based lipid mediator profiling. Many SPMs were significantly reduced in septic hearts, among which RvE1 had a ~93-fold reduction. Treatment of CLP mice with synthetic RvE1 (1 μg/mouse
Identifiants
pubmed: 32983159
doi: 10.3389/fimmu.2020.02080
pmc: PMC7492649
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Eicosapentaenoic Acid
AAN7QOV9EA
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
GND3JH08JA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2080Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107613/Z/15/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Chen, Purvis, Collotta, Al Zoubi, Sugimoto, Cacace, Martin, Colas, Collino, Dalli and Thiemermann.
Références
Crit Care Med. 2001 Jul;29(7):1303-10
pubmed: 11445675
Kidney Int. 2013 Sep;84(3):482-90
pubmed: 23594675
Ann Surg. 2007 Jun;245(6):971-7
pubmed: 17522524
N Engl J Med. 2017 Jun 8;376(23):2223-2234
pubmed: 28320242
J Crit Care. 2019 Dec;54:228-234
pubmed: 31630071
Nature. 1993 Sep 9;365(6442):182-5
pubmed: 8371761
FASEB J. 2018 Jul;32(7):3816-3831
pubmed: 29465314
Prostaglandins Leukot Essent Fatty Acids. 2011 Jan-Feb;84(1-2):43-50
pubmed: 20869861
Nature. 2012 Apr 25;484(7395):524-8
pubmed: 22538616
Am J Respir Crit Care Med. 2010 Dec 15;182(12):1506-15
pubmed: 20693380
Dis Model Mech. 2013 Jul;6(4):1012-20
pubmed: 23592614
Front Pharmacol. 2020 Mar 18;11:203
pubmed: 32256344
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Dis Model Mech. 2013 Jul;6(4):1021-30
pubmed: 23519033
J Exp Med. 2005 Mar 7;201(5):713-22
pubmed: 15753205
N Engl J Med. 2001 Nov 8;345(19):1368-77
pubmed: 11794169
Clin Sci (Lond). 2014 Jun;126(11):805-14
pubmed: 24344649
Crit Care Med. 2002 Jan;30(1 Suppl):S18-26
pubmed: 11782557
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):253-62
pubmed: 16198162
Diabetologia. 2018 Feb;61(2):482-495
pubmed: 29085990
Cell Rep. 2014 Oct 23;9(2):591-604
pubmed: 25373902
J Innate Immun. 2013;5(4):367-76
pubmed: 23635943
J Immunol. 2015 Mar 1;194(5):2330-7
pubmed: 25637017
Front Pharmacol. 2018 Nov 14;9:1273
pubmed: 30487747
FASEB J. 2017 Apr;31(4):1273-1288
pubmed: 28087575
Nature. 2009 Oct 29;461(7268):1287-91
pubmed: 19865173
Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54
pubmed: 24696140
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18685-90
pubmed: 25512512
Br J Pharmacol. 2018 Apr;175(8):1205-1216
pubmed: 28925017
J Exp Med. 2000 Oct 16;192(8):1197-204
pubmed: 11034610
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Front Immunol. 2018 Oct 23;9:2446
pubmed: 30459764
Crit Care. 2008;12(6):R158
pubmed: 19091069
Biochem Pharmacol. 2016 Sep 15;116:107-19
pubmed: 27475716
PLoS One. 2011;6(9):e24422
pubmed: 21935407
Crit Care Med. 2018 Apr;46(4):625-634
pubmed: 29227368
J Immunol. 2011 Jun 1;186(11):6129-35
pubmed: 21515793
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H153-64
pubmed: 20435846
J Exp Med. 2002 Oct 21;196(8):1025-37
pubmed: 12391014
Crit Care Med. 2017 Jan;45(1):58-68
pubmed: 27632672
PLoS One. 2014 Jun 19;9(6):e100631
pubmed: 24945834
Blood. 2012 Oct 11;120(15):e60-72
pubmed: 22904297
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
J Am Soc Nephrol. 2017 Jan;28(1):94-105
pubmed: 27153924
J Biol Chem. 2010 Jan 29;285(5):3451-61
pubmed: 19906641
Br J Pharmacol. 2020 Jul 1;:
pubmed: 32608058
J Immunol. 2010 Jan 15;184(2):836-43
pubmed: 20007539
Curr Protoc Bioinformatics. 2019 Dec;68(1):e86
pubmed: 31756036
Circulation. 2018 Oct 16;138(16):1693-1705
pubmed: 29739755